The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

CompletedOBSERVATIONAL
Enrollment

788

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

December 20, 2023

Study Completion Date

May 2, 2024

Conditions
Newly-diagnosed CancersNon-cancer Controls
Interventions
DIAGNOSTIC_TEST

Freenome Test

Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.

Trial Locations (23)

17815

Geisinger Bloomsburg Hospital, Bloomsburg

22031

INOVA, Fairfax

28677

Iredell Memorial Hospital, Statesville

29425

MUSC, Charleston

29506

MacLeod Center for Cancer Treatment and Research, Florence

31015

Crisp Regional Hospital, Cordele

44195

Cleveland Clinic, Cleveland

47006

Silver Cross Hospital and Medical centers, Orland Park

Margaret Mary, Batesville

48202

Henry Ford Health, Detroit

53215

Aurora St. Luke's Medical Center, Milwaukee

55407

Allina Health Cancer Institute, Minneapolis

55987

Winona Health System, Winona

60068

Advocate Lutheran General Hospital, Park Ridge

63401

Hannibal Regional Hospital, Hannibal

64108

University Health Truman Medical Center, Kansas City

64116

North Kansas City Hospital, North Kansas City

64633

Carroll County Memorial Hospital, Carrollton

78738

Elligo Health Research, Inc., Austin

89502

Renown Regional Medical Center, Reno

97201

Oregon Health and Science University, Portland

08062

Inspira Medical Center, Mullica Hill

07503

St Joseph University, Paterson

All Listed Sponsors
lead

Freenome Holdings Inc.

INDUSTRY